Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the antitumor activity of SU011248 in advanced, imatinib mesylate-resistant
gastrointestinal stromal tumor (GIST) when administered on a continuous daily dosing schedule